World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00810030
Date of registration: 16/12/2008
Prospective Registration: No
Primary sponsor: Vifor Inc.
Public title: FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR FER-IBD-COR
Scientific title: Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease
Date of first enrolment: October 2008
Target sample size: 484
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00810030
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 3
Countries of recruitment
Austria Russian Federation
Contacts
Name:     Christoph Gasche, Professor
Address: 
Telephone:
Email:
Affiliation:  Medical University of Vienna
Key inclusion & exclusion criteria

Inclusion Criteria

- Signed informed consent.

- Patients =18 years of age suffering from mild IBD (CD/UC) or in remission (mild IBD
defined as CDAI score <220, or CAI score =7, remission defined as CDAI score <150, or
CAI score =4).

- Hb 7-12 g/dL (female) or 7-13 g/dL (male).

- Ferritin <100 µg/L.

- Normal levels of vitamin B12 and folic acid.

- Females of child-bearing potential must have a negative urine pregnancy test at
screening and be practising an acceptable method of birth control during the study
and for up to 1 month after the last dose of study medication.

Exclusion Criteria

- Chronic alcohol abuse (alcohol consumption >20 g/day).

- Presence of portal hypertension with oesophageal varices.

- History of erythropoietin, intravenous or oral iron therapy, or blood transfusion in
4 weeks prior to screening.

- Known hypersensitivity to FERINJECT®.

- History of acquired iron overload.

- Myelodysplastic syndrome.

- Pregnancy or lactation.

- Known active infection, clinically significant overt bleeding, active malignancy.

- Known chronic renal failure. Vifor Pharma - Vifor (International) Inc Clinical Study
Protocol inc. Amendments 1 and 2 Protocol Number: 93842, FER-IBD-07-COR CONFIDENTIAL
Final 20 of 48 10 December 2008

- Surgery with relevant blood loss (defined as Hb drop <2 g/dL) in the last 3 months
prior to screening or planned surgery within the following 3 months.

- Chronic liver disease or increase of liver enzymes (alanine aminotransferase ([ALT],
aspartate aminotransferase [AST]) >3 times the upper limit of normal range.

- Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS),
hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

- Inability to fully comprehend and/or perform study procedures in the investigator's
opinion.

- Participation in any other interventional study within 1 month prior to screening.

- Body weight <35 kg.

- Significant cardiovascular disease, including myocardial infarction within 12 months
prior to study inclusion, congestive heart failure NYHA (New York Heart Association)
grade III or IV, or poorly controlled hypertension according to the judgment of the
investigator.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Iron-Deficiency Anemia
Crohn's Disease
Inflammatory Bowel Disease
Iron Deficiency
Anemia
Ulcerative Colitis
Intervention(s)
Drug: Iron Sucrose
Drug: Ferric carboxymaltose
Primary Outcome(s)
Number of responders with respect to the baseline Hb value. [Time Frame: 12 weeks post baseline]
Secondary Outcome(s)
Hospitalisation rate [Time Frame: 12 weeks post baseline]
Number of patients whose Hb increased =2 g/dL or who reached normal Hb levels at Week 12. [Time Frame: 12 weeks post baseline]
The number of patients out of work due to anaemia or IBD. [Time Frame: 12 weeks post baseline]
The number of non-anaemic patients at Week 12 [Time Frame: Week 12 post baseline]
Physical examination. [Time Frame: 12 weeks post baseline]
The number of patients with ferritin >100 µg/L at Week 12. [Time Frame: 12 weeks post baseline]
The number of patients with Hb baseline value =10 g/dL who achieved Hb increase =2 g/dL and the number of patients with Hb baseline value >10 g/dL who achieved Hb increase =2 g/dL. [Time Frame: 12 weeks post baseline]
The number of patients at Week 12: TfS: 20 to 50%. [Time Frame: 12 weeks post baseline]
Adverse events: type, nature, incidence and outcome. [Time Frame: 12 weeks post baseline]
Days out of hospital. [Time Frame: 12 weeks post baseline]
Change in disease activity (CDAI, CAI, C-reactive protein [CRP]). [Time Frame: 12 weeks post baseline]
Change in health-related quality of life (QoL) from baseline to Week 12 using the Short Form (SF)-36, version 2 and IBDQ. [Time Frame: 12 weeks post baseline]
Electrocardiogram. [Time Frame: 12 weeks post baseline]
The number of responders (Hb increase =2 g/dL) with respect to treatment of underlying disease. [Time Frame: 12 weeks post baseline]
Change in laboratory parameters (haematology, clinical chemistry, iron status, urinalysis). [Time Frame: 12 weeks post baseline]
The number of responders (Hb increase =2 g/dL) with respect to the baseline Hb value. [Time Frame: 12 weeks post baseline]
Vital signs (blood pressure, pulse rate and bw). [Time Frame: 12 weeks post baseline]
Maximum increase in Hb, serum ferritin and TfS. [Time Frame: 12 weeks post baseline]
The number of patients at achieving Hb =12 (female) or =13 (male) g/dL and ferritin >100 µg/L at Week 12. [Time Frame: 12 weeks post baseline]
The number of patients withdrawal from study due to protocol procedure. [Time Frame: 12 weeks post baseline]
Secondary ID(s)
FER-IBD-07-COR
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Parexel
ClinStar
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey